Abstract: There are described compounds of formula I, ##STR1## in which X represents a C2 to 8 alkylene chain optionally interrupted by a double bond or by S(O).sub.n, wherein n is 0, 1 or 2;Y represents O or NH,l and m each independently represent 2, 3 or 4,R.sub.10 represents phenyl substituted by one or more substituents R.sub.23, which may be the same or different; or R.sub.10 represents pyridyl, a saturated carbocyclic group, alkyl C 1 to 6 or hydrogen,R.sub.15 represents hydrogen or together with R.sub.23 forms a (CH.sub.2).sub.p chain, wherein p represents 0, 1 or 2;R.sub.20, R.sub.21, R.sub.22 and R.sub.23, which may be the same or different, independently represent hydrogen, alkyl C 1 to 6, NHR.sub.25, SH, NO.sub.2, halogen, CF.sub.3, SO.sub.2 R.sub.30, CH.sub.2 OH or OH, wherein R.sub.25 represents hydrogen, alkyl C 1 to 6, alkanoyl C 1 to 6 or SO.sub.2 alkyl C 1 to 6, and R.sub.30 represents alkyl C 1 to 6 or NH.sub.

Abstract: A pharmaceutical composition comprising, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof in admixture with a pharmaceutical acceptable adjuvant or excipient, the composition being suitable for topical administration to a patient's skin but not suitable for administration orally or to the patient's eye.Also described are methods of treatment of various dermatological disorders comprising topical administration to the skin of a patient suffering from such a disorder of a therapeutically effective quantity of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof.

Abstract: There are provided compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

Abstract: A method of treatment of cystic fibrosis which comprises administration to a patient suffering from that condition of a therapeutically effective quantity of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof.Pharmaceutically acceptable salts of the active ingredient which may be used include alkali metal salts, in particular the di-sodium salt which is known as nedocromil sodium.

Abstract: There are described compounds of formula I, ##STR1## in which A is a benzene or heterocyclic ring, y is 0 or 1,L is a group containing 1 or 2 carbon atoms, or is a single bond,R.sub.9 and R.sub.10 have a variety of significances, e.g.R.sub.10 may form part of a double bond with L, orthe group --NR.sub.9 R.sub.10 forms a ring carrying substituents R.sub.1 and R.sub.8, orwhen L is a single bond --NR.sub.10 and R.sub.8 may form a ring carrying substituents R.sub.16 to R.sub.25, orthe group --LNR.sub.9 R.sub.10 forms a heterocyclic ring carrying substituents R.sub.26 to R.sub.33,R.sub.1 to R.sub.8 and R.sub.16 to R.sub.33 have a variety of significancesn is 0, 1 or 2,x is 3, 4 or 5,X is S, O or NR.sub.15,R.sub.15 is hydrogen, --COR, --COOR or alkyl optionally substituted by --OCOR,and certain provisos.Processes for making the compounds and pharmaceutical formulations containing them, e.g. for the treatment of conditions involving excess gastric acid secretion, are also described.

Abstract: There are described a new compound, methods for its preparation and compositions containing it.Calcium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dic arboxylate is a novel compound and is useful in the treatment of reversible obstructive airways disease and/or the prevention or treatment of rhinitis.

Abstract: There is described the calcium salt of 10-propyl-2,8-bis(1H-tetrazol-5-yl)-4H,6H-benzo(1,2-b;5,4-b')dipyran-4,6- dione and processes for its preparation.Also described are pharmaceutical compositions containing the calcium salt and methods of treatment involving its use.

Abstract: Pharmaceutical compositions comprising microspheres incorporating sodium cromoglycate, wherein the microspheres comprise material having ion-exchange properties.

Abstract: There are described compounds of formula I, ##STR1## in which Ar.sub.1 and Ar.sub.2, which may be the same or different, each independently represent phenyl or pyridinyl, the phenyl or the pyridinyl each optionally being substituted by one or more of halogen; hydroxy; --COOR.sub.12 ; trihalomethyl; alkoxy C1 to 6; alkyl C1 to 6; --NR.sub.1 R.sub.2 ; alkoxy C1 to 6 substituted by --NR.sub.1 R.sub.2 or by phenyl; or alkyl C1 to 6 substituted by --NR.sub.1 R.sub.2 or by --COOR.sub.12 ;R.sub.1 and R.sub.2, which may be the same or different, each independently represent hydrogen or alkyl C1 to 6,R.sub.3 represents hydrogen, alkyl C1 to 6, alkanoyl C1 to 6, benzoyl, --COOR.sub.8, or --CONHR.sub.11,R.sub.4, R.sub.5, R.sub.6 and R.sub.7, which may be the same or different each independently represent hydrogen, alkyl C1 to 6 or phenyl,R.sub.8 represents alkyl C1 to 6 or aryl,R.sub.11 represents alkyl C1 to 6 or aryl,R.sub.12 represents hydrogen or alkyl C1 to 6, and pharmaceutically acceptable derivatives thereof.

Abstract: There are described compounds of formula I, ##STR1## in which either R.sub.2 represents hydrogen, alkyl or Ar.sub.2, andR.sub.3 represents hydrogen, alkyl or alkyl substituted by Ar.sub.3 ;or R.sub.2 and R.sub.3 together form the chain --(CH.sub.2).sub.m --;R.sub.4 and R.sub.5, which may be the same or different, each independently represent hydrogen, halogen, Ar, alkyl, or alkyl substituted by Ar,Ar.sub.1, Ar.sub.2 and Ar, which may be the same or different each independently represent aryl or aryl substituted by one or more ofhalogen, hydroxy, --CN, --COR.sub.6, trihalomethyl, alkoxy, alkoxy substituted by --COR.sub.6, alkoxy substituted by --NR.sub.7 R.sub.8, alkyl, alkyl substituted by --COR.sub.6, alkyl substituted by NR.sub.7 R.sub.8, alkoxy substituted by Ar.sub.3, S(O).sub.n R.sub.9, --NR.sub.7 R.sub.8 or OAr.sub.3 ;R.sub.6 represents --OR.sub.10, --NR.sub.7 R.sub.8, hydrogen or alkyl;R.sub.7 and R.sub.8, which may be the same or different, each independently represent hydrogen, alkyl, alkanoyl or Ar.

Abstract: There is described a pharmaceutical composition comprising liposomes and sodium cromoglycate.There is also described an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase.There is further described a method for making the compositions, and their use in the treatment of allergic conditions, e.g., asthma.

Abstract: There are described compounds of formula I, ##STR1## in which R.sub.1 represents hydrogen, alkyl, alkanoyl or alkyl substituted by Ar.sub.1,R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, each independently represent hydrogen, alkyl or Ar.sub.3,Ar.sub.1, Ar.sub.2 and Ar.sub.3, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of alkyl, hydroxy, alkoxy, NR.sub.6 R.sub.7 or halogen,R.sub.6 and R.sub.7, which may be the same or different, independently represent hydrogen or alkyl,and pharmaceutically acceptable acid addition salts thereof.Compositions containing the compounds and methods for their preparation are also described.The compounds are indicated for use as pharmaceutical, e.g. anti-inflammatory, agents.

Abstract: There are provided compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

Abstract: Aqueous rooting gel which comprises a thixotropic gel of hectorite in water containing at least 60 ppm, and preferably not more than 200 ppm calcium ions. There is also provided a transparent container including such a rooting gel. The gels are useful for rooting a wide variety of soft wood cuttings, eg fuchsia and geranium.

Abstract: There are provided paraethylamine phenol compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

Abstract: A photometric reading device comprises a plurality of reading elements (30), each comprising a light emitting diode and a corresponding photodiode on opposing sides of a sample pathway along which a sample microplate (10) can travel. The microplate (10) includes rows of sample wells arranged transverse to the line of relative motion of the microplate (10) and the reading elements (30).The reading elements (30) are arranged such that, during continuous relative motion of the reading elements (30) and the microplate (10), the reading elements (30) come into registration sequentially with the wells in the first row of wells in the microplate (10), then with the wells in the second row of wells, and so on.

Abstract: There are described new forms of nedocromil sodium, methods of producing these new forms and pharmaceutical formulations, especially pressurized inhalation aerosol formulations, containing finely divided nedocromil sodium. The formulations are indicated for the treatment of reversible obstructive conditions of the airways.

Abstract: There are described compounds of formula I,ZCHRCON(--N.dbd.CR.sub.4 R.sub.5)CHR.sub.6 (CH.sub.2).sub.n COY Iwhere the substituents are defined in the disclosure.There are also described methods for making the compounds, formulations containing them and their use, e.g. as antihypertensives.

Abstract: There are provided compounds of formula I, ##STR1## in which R.sub.1 represents OH,R.sub.2 and R.sub.3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitro, nitrile, (CH.sub.2).sub.p R.sub.9 or SR.sub.9,W represents a single bond, a 1,2; 1,3; or 1,4-disubstituted benzene ring; a --CH.dbd.CH--group or a 1,4-cyclohexanediyl group;X respresents NH, O, S, SO.sub.2, CO, CH.sub.2, CONH or --COO;Y represents (CH.sub.2)q, CO, CS, SO.sub.2 and R.sub.20 represents hydrogen,or Y represents CR.sub.15 R.sub.16 CR.sub.17 R.sub.18,wherein the carbon atom bearing R.sub.15 and R.sub.16 is adjacent to X and in whichR.sub.15 and R.sub.18, together with the carbon atom to which they are attached form a carbonyl group, and R.sub.15, R.sub.16 and R.sub.20 each represent hydrogen, orR.sub.15 and R.sub.20 together form a chain --CH.sub.2 --, and R.sub.16, R.sub.17 and R.sub.18 each represent hydrogen, orR.sub.15, R.sub.16, R.sub.17 and R.sub.

Abstract: There is described a water soluble compound having a molecular weight of from about 70,000 to about 2,000,000, and having the formula I,(PS)--X--(HB)--Z IwherePS represents a physiologically acceptable polysaccharide of molecular weight from about 2,000 to about 2,000,000,X represents a covalently bonded chemical bridging group,HB represents a haemoglobin residue, andZ represents an oxygen affinity reduced ligand, containing 2 or more phosphate groups.There is also described haemoglobin linked to an oxygen affinity reducing ligand derived from inositol phosphate, and polymers of such linked haemoglobin.Processes for making the compounds, and their formulation and use as oxygen transporting agents, are also described.